跳转至内容
Merck
所有图片(1)

Key Documents

SML0241

Sigma-Aldrich

Ganirelix acetate salt

≥95% (HPLC), lyophilized powder, GnRH antagonist

别名:

Antagon, N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]-L-lysyl-L-prolyl-D-alaninamide diacetate, Orgalutran

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C80H113ClN18O13 · 2C2H4O2
CAS号:
129311-55-3
分子量:
1690.42
分類程式碼代碼:
51111800
NACRES:
NA.77

product name

Ganirelix acetate salt, ≥95% (HPLC)

化驗

≥95% (HPLC)

形狀

lyophilized powder

顏色

white

儲存溫度

−20°C

InChI

1S/C80H113ClN18O13.2C2H4O2/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54;2*1-2(3)4/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89);2*1H3,(H,3,4)/t50-,60-,61+,62+,63?,64-,65+,66+,67-,68?;;/m1../s1

InChI 密鑰

OVBICQMTCPFEBS-HYVLHXRFSA-N

生化／生理作用

Ganirelix is a decapeptide GnRH antagonist. Ganirelix acts by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH.

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H315,H319,H335

危險分類

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

N E Kummer et al.
Human reproduction (Oxford, England), 28(1), 152-159 (2012-10-19)
Are there factors predicting the number of total and mature oocytes retrieved after controlled ovarian hyperstimulation (COH) utilizing a gonadotropin-releasing hormone (GnRH) antagonist protocol and a GnRH agonist (GnRHa) to induce oocyte maturation? Peak estradiol (E₂) level, post-trigger LH and
Vienna E Brunt et al.
American journal of physiology. Heart and circulatory physiology, 305(7), H1041-H1049 (2013-07-23)
The individual effects of estrogen and progesterone on baroreflex function remain poorly understood. We sought to determine how estradiol (E2) and progesterone (P4) independently alter the carotid-cardiac and carotid-vasomotor baroreflexes in young women by using a hormone suppression and exogenous
Francisca Martínez et al.
European journal of obstetrics, gynecology, and reproductive biology, 159(2), 355-358 (2011-07-06)
The synchronization of the donor stimulation with the endometrial preparation of the recipient is usually done by downregulating the recipient's pituitary with a GnRH analog. The aim of this study is to compare pregnancy and implantation rates among premenopausal oocyte
Nicole Kummer et al.
Fertility and sterility, 96(1), 63-68 (2011-05-14)
To determine factors predicting cycle success after in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) in high-risk patients undergoing controlled ovarian stimulation with a gonadotropin-releasing hormone (GnRH) antagonist protocol with a GnRH agonist to induce oocyte maturation. Retrospective cohort
Nikolaos P Polyzos et al.
Reproductive biomedicine online, 24(5), 532-539 (2012-03-16)
Evidence regarding the role of anti-Müllerian hormone (AMH) among oocyte donors is limited and only involves gonadotrophin-releasing hormone (GnRH)-agonist-treated donors. This trial assessed the predictive ability of AMH for ovarian response among 108 oocyte donors treated with an antagonist protocol.
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门